Quote:
The US Food and Drug Administration (FDA) said the first clinical trial to test a new stem cell treatment for the fatal neurodegenerative disease ALS (amyotrophic lateral sclerosis) this month (ALS) can go ahead
The drug, which comprises the company’s own patented neural stem cells, is administered as a series of injections at different sites along the spinal cord.
The trial will study the safety of Neuralstem’s cells and the surgical procedures and devices required for multiple injections of the drug directly into the grey matter of the spinal cord.
For the first phase of the trial, which is being paid for by the drug company, Feldman and colleagues will be treating 12 of 18 recruited patients with varying degress of ALS. The 12 patients will receive between five and ten injections of stem cells into the lumbar region of the spinal cord. They will be examined regularly for up to two years after the operation at which point the data will be reviewed.
In addition to ALS, the company is hoping to use its new technology to target other major central nervous system diseases such as Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury and Huntington’s disease.
|
SOURCE
This has probably already been posted, but isn't this nearly identical
to what Wise is planning to do?
10-11-2009, 10:43 PM
Similar Threads
Linear Mode
